Position in ARVN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$684,021
-$2,072,148 QoQ
Shares Held
82,313
-68.3% QoQ
Ownership
0.126%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#69
of 201 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ARVN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026CAXTON ASSOCIATES LLP holds $10,474,989 across 15 Biotechnology names. ARVN ranks #7 (6.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LGND |
Ligand Pharmaceuticals Inc
|
5,854 | $1,850,390 | |
| 2 | DNA |
Ginkgo Bioworks Holdings, Inc.
|
154,647 | $1,532,551 | |
| 3 | AXSM |
Axsome Therapeutics, Inc.
|
4,290 | $1,050,063 | |
| 4 | ZVRA |
Zevra Therapeutics, Inc.
|
70,048 | $1,004,488 | |
| 5 | TECH |
BIO-TECHNE Corp
|
10,296 | $727,412 | |
| 6 | MRVI |
Maravai Lifesciences Holdings, Inc.
|
112,479 | $701,868 | |
| 7 | ARVN |
Arvinas, Inc.
This page
|
82,313 | $684,021 | |
| 8 | RNA |
Atrium Therapeutics, Inc.
|
44,230 | $594,893 |
All Filings in ARVN
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $684,021 | 82,313 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $2,756,169 | 260,016 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $5,390,571 | 454,517 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $5,152,768 | 604,785 | Shares | Sole | 2025-11-17 | |
| 2025-06-30 | $2,193,736 | 298,062 | Shares | Sole | 2025-08-15 | |
| No filing history on record for this holder in this stock. | ||||||